Skip to main content
. 2020 Jan 17;20:58. doi: 10.1186/s12879-020-4787-4

Fig. 6.

Fig. 6

Significant increases in the % of CMV-specific CD4+ (left) and CD8+ (right) T-cells with time, after the initial CMV event (Wilcoxon rank sum P = 0.028). Five of six patients (black lines), who all had > 0.22% CMV-specific CD4+ T-cells on repeat testing, did not experience subsequent CMV events after discontinuation of valganciclovir (Reference lines: 0.22 and 0.21% for CD4+ and CD8+, respectively, as explained in the text)